What does a positive HLA‑B8 result indicate and what clinical implications or screening should be considered?

HLA-B8: Clinical Significance and Implications

HLA-B8 is a genetic marker associated with increased susceptibility to multiple autoimmune conditions, but it is NOT the primary HLA allele tested for celiac disease—you need to test for HLA-DQ2 and HLA-DQ8 instead.

What HLA-B8 Actually Indicates

HLA-B8 is a class I HLA allele that appears in approximately 10-25% of Caucasian populations and serves as a genetic susceptibility marker for various autoimmune and immune-mediated diseases. However, its clinical utility is limited compared to disease-specific HLA testing.

Key Disease Associations

Autoimmune Conditions with Strong HLA-B8 Association:

• Primary Sclerosing Cholangitis: 60% of patients carry HLA-B8 versus 25% of controls, representing a significant disease susceptibility marker 1. Patients with ulcerative colitis and HLA-B8 may be particularly prone to developing PSC.

• Autoimmune Hepatitis: HLA-B8-positive patients present younger (38 vs 48 years) with more severe disease, higher transaminases (658 vs 465 U/L), and higher bilirubin levels (7 vs 2.8 mg/dl) 2. However, HLA-B8 does NOT influence response to corticosteroid therapy or long-term outcomes.

• Systemic Lupus Erythematosus: 64% of SLE patients carry HLA-B8 versus 22% of controls, with particularly strong associations in Ro antibody-positive (82%) and Ha antibody-positive (84%) patients 3.

• Type 1 Diabetes: HLA-B8 frequency is significantly elevated in diabetic infants (14.5% vs 5% in controls), though it shows unmarked linkage disequilibrium with the DR3-DQA105-DQB102 haplotype in Egyptian populations 4.

• Anti-CarP Positive Rheumatoid Arthritis: HLA-B*08 (specifically the Asp-9 variant) is the most prominently associated MHC locus for anti-carbamylated protein antibody-positive/anti-CCP-negative RA 5.

Protective Effects:

• Chronic Myeloid Leukemia: HLA-B8 confers 27% protection against CML development, with 49% protection when coexpressed with HLA-A3 6. This may reflect immune recognition of bcr-abl fusion peptides.

Critical Clinical Caveat: Celiac Disease Testing

The provided guidelines 7 discuss HLA testing for celiac disease but focus exclusively on HLA-DQ2 and HLA-DQ8—NOT HLA-B8. For suspected celiac disease:

• Test for HLA-DQ2.5 (DQA10501, DQB10201), HLA-DQ8 (DQA103, DQB10302), HLA-DQ2.2 (DQA10201, DQB10202), and HLA-DQ7.5 (DQA105, DQB10301)
• Nearly 100% of celiac disease patients carry DQ2 and/or DQ8 8
• Negative HLA-DQ2/DQ8 testing effectively rules out celiac disease
• HLA-B8 testing has NO role in celiac disease diagnosis

When to Order HLA-B8 Testing

Do NOT routinely order HLA-B8 testing. It has limited clinical utility because:

1. High population frequency (10-25%) means poor positive predictive value
2. No therapeutic implications in most conditions
3. Disease-specific HLA testing (like DQ2/DQ8 for celiac) is more clinically relevant

Consider HLA-B8 testing only in:

• Research settings examining autoimmune disease susceptibility
• Family counseling for multiple autoimmune conditions when HLA-B8 is documented in affected family members
• Specific clinical scenarios where understanding genetic risk stratification may influence surveillance intensity (e.g., PSC screening in ulcerative colitis patients)

Practical Management Approach

If HLA-B8 is incidentally discovered or specifically tested:

1. Document the finding but recognize it does NOT diagnose any specific condition
2. Maintain clinical vigilance for autoimmune conditions, particularly if symptoms develop
3. Do NOT initiate disease-specific screening based solely on HLA-B8 positivity
4. Screen based on clinical presentation, family history, and disease-specific guidelines—not HLA-B8 status alone

Common Pitfall: Ordering HLA-B8 when you actually need HLA-DQ2/DQ8 testing for celiac disease evaluation. Always verify which specific HLA alleles are clinically indicated for the suspected condition.